Exact Sciences (EXAS) Spec Buy Reiterated at Benchmark; Co. Anything But Revenue and Earnings Story
Benchmark maintained a Speculative Buy rating on Exact Sciences (NASDAQ: EXAS) with a price target of $25.00. Comments follow Q1 ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)